Sarepta to Commence Dosing of Next Study with Commercial Process Material for SRP-9001 Gene Therapy
We are encouraged by the result of Sarepta’s Type C meeting with the FDA. Type C meetings are a “catch all” category and include any topics concerning the development and review of a product. This…Learn More